These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25630635)

  • 1. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea.
    Cho MH; Yoo KB; Lee HY; Lee KS; Kwon JA; Han KT; Kim JH; Park EC
    Health Policy; 2015 May; 119(5):604-11. PubMed ID: 25630635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.
    Yoo KB; Lee SG; Park S; Kim TH; Ahn J; Cho MH; Park EC
    BMJ Open; 2015 Jul; 5(7):e006940. PubMed ID: 26179644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
    Lee IH; Bloor K; Hewitt C; Maynard A
    Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
    Chen CL; Chen L; Yang WC
    BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pharmaceutical cost containment policies on doctors' prescribing behavior: Focus on antibiotics.
    Han E; Chae SM; Kim NS; Park S
    Health Policy; 2015 Sep; 119(9):1245-54. PubMed ID: 26119997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
    Kwon HY; Hong JM; Godman B; Yang BM
    Health Policy; 2013 Oct; 112(3):217-26. PubMed ID: 24075008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea.
    Kim JY; Kim SJ; Nam CM; Moon KT; Park EC
    Eur J Public Health; 2018 Apr; 28(2):209-214. PubMed ID: 29579210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perception and attitude of Korean physicians towards generic drugs.
    Ryu M; Kim J
    BMC Health Serv Res; 2017 Aug; 17(1):610. PubMed ID: 28851368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving cost-effectiveness of hypertension management at a community health centre.
    Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
    S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical expenditure in Spain: cost and control.
    Lopez Bastida J; Mossialos E
    Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
    Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
    Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
    Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
    CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.